The Union Ministry of Health claimed that there was a ‘negative’ number of covisheild blood clotting cases in Indians receiving the Covid 19 vaccination (named Covishield) of AstraZeneca. As The Indian Ministry of Health said in a statement, citing a report of the National AEFI Committee: “AEFI (Adverse Events Following Immunization) has shown that there is a very minuscule, yet definitive risk of thromboembolic events.”.
Thromboembolic events involve developing a blood vessel coagulation that could also come out and obstruct the bloodstream into a different vessel.
In particular, for the serum Institute Covishield, in India, the national committee monitoring the adverse event of Covid-19 has stated that the risk of blood clots (thromboembolic events) post Covid-19 immunisation is very low. However, the Ministry of Health, which has received the Committee report on this subject, will provide medical and vaccination beneficiaries with advisories to encourage. Individuals are alert of suspected thromboembolic symptoms that arise within 20 days of receiving any Covid-19 vaccine and report these events to the healthcare facility that gave the vaccine.
In India, there are just a few cases of covisheild blood clotting. Meanwhile, the national adverse effect following immunization (AEFI) committee reported to the health minister on Monday that bleeding and clotting cases after Covid vaccination in India are “minuscule and in line with the estimated number of diagnoses of these conditions in the country.”
After warnings of rare brain blood clots following vaccination, several European countries suspended their use of the AstraZeneca Covid-19 vaccine produced in India by SII under the brand name “Covishield.”
Most countries, however, have restored vaccination after European Union and British authorities determined that the vaccine’s benefits outweigh its risks.
Following the administration of the Covaxin vaccine, there identified no thromboembolic cases. “Thromboembolic” symptoms are a minimal but significant risk.
In India, these blood clotting type incidents registered at a rate of about 0.61/million doses, which is significantly lower than the UK’s Medical and Health Regulatory Authority’s 4 cases per million (MHRA). Ten cases per million doses were registered in Germany, “It had said.